GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena
GSK secures rights to Boston Pharmaceuticals’ efimosfermin alfa, which the pharma plans to develop for fatty liver diseases such as metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease.
GSK Buys Phase III–Ready Liver Drug in Potential $2B Deal To Play in MASH Arena Read More »
